Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477579 | 1.00 | CYP1A2 (0.48) | CYP1A2TSHRCYP2C19CYP11B2HPGD | |
| SCHEMBL23020647 | 1.00 | CYP1A2 (0.48) | CYP1A2TSHRCYP2C19CYP11B2HPGD | |
| SCHEMBL13591320 | 1.00 | CYP1A2 (0.48) | CYP1A2TSHRCYP2C19CYP11B2HPGD | |
| SCHEMBL12749374 | 1.00 | CYP1A2 (0.48) | CYP1A2TSHRCYP2C19CYP11B2HPGD | |
| SCHEMBL1477925 | 0.92 | HPGD (0.49) | CYP1A2TSHRCYP2C19HPGDFFAR1 | |
| SCHEMBL12749381 | 0.92 | HPGD (0.49) | CYP1A2TSHRCYP2C19HPGDFFAR1 | |
| SCHEMBL12749371 | 0.86 | TSHR (0.50) | CYP1A2TSHRCYP2C19KDM4EMAPT | |
| SCHEMBL1477578 | 0.86 | TSHR (0.50) | CYP1A2TSHRCYP2C19KDM4EMAPT | |
| SCHEMBL1477389 | 0.86 | TSHR (0.50) | CYP1A2TSHRCYP2C19KDM4EMAPT | |
| SCHEMBL22209851 | 0.86 | TSHR (0.50) | CYP1A2TSHRCYP2C19KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | CYP1A2 1896/4885TSHR 1578/4885CYP2C19 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.